PNP THERAPEUTICS INC

BIRMINGHAM, AL · Biotech · Private

Gedeptin platform technology and proprietary cancer therapeutics

Claim this profile

Follows are private to you and power your alerts

Updated · pnptherapeutics.com

Sector
Biotech
Headquarters
BIRMINGHAM, AL
Latest Form D
$124K, Aug 2018
Total capital
$1.7M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$1.7M
5 Form D · last Aug 2018
98 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2012201320142015201620172018FEDERAL ↑EQUITY ↓Cumulative $1.7M1st Form D$673K3rd Form D$394K4th Form D$287K5th Form D$124K
2012201420162018FEDERAL ↑EQUITY ↓Cumulative $1.7M4th Form D$287K

Latest events

  • Private capital raisedForm D · SEC · 5th filing$124K
  • Private capital raisedForm D · SEC · 4th filing$287K
  • Private capital raisedForm D · SEC · 3rd filing$394K
  • Private capital raisedForm D · SEC · 2nd filing$212K
  • Private capital raisedForm D · SEC · 1st filing$673K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Charles K. PorterDirectorNamed in SEC Form D filings
  • Claude F. BennettDirectorNamed in SEC Form D filings
  • David A. DoddDirectorNamed in SEC Form D filings
  • Eric W SorscherDirectorNamed in SEC Form D filings
  • Frank R. HuntExecutive OfficerNamed in SEC Form D filings
  • James F FuquaExecutive Officer, DirectorNamed in SEC Form D filings
Show all 10 people
  • John K LankfordDirectorNamed in SEC Form D filings
  • Lawrence W GreerDirectorNamed in SEC Form D filings
  • William B. DealDirectorNamed in SEC Form D filings
  • William B ParkerExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Porosome Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • CRISPRQC INC.Similar federal contract value in Biotech · null in contracts
  • BioFactura, Inc.Similar federal contract value in Biotech · null in contracts
  • Nu-Tek BioSciences, LLCSimilar federal contract value in Biotech · null in contracts
  • CORE ONE LABS INC.Similar federal contract value in Biotech · null in contracts
  • ADDUCTNE LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .